Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

Cell Host & Microbe: 运用突变技术发明减活流感疫苗，防御多种流感病毒感染

2017-03-10 Leo.C MedSci原创

流感疫苗减活疫苗突变
关注

基于活病毒采用突变和高通量筛选技术快速开发流感病毒疫苗

基于减活性病毒的疫苗（live attenuated vaccine）能够产生更强的更持久的体液免疫（humoral immunity）和细胞免疫(cellular immunity)反应。但是减活病毒的过程，以及筛选具有保护作用的减活病毒需要一定的时间。减活病毒疫苗的安全性也是一个重要问题。

在新一期的Cell Host & Microbe杂志中，Lulan Wang及其同事基于活流感病毒，运用全基因组诱导突变技术，以及一种高效筛选流程，筛选出一种减活性的流感病毒疫苗W7-791。该种疫苗具有很高的安全性。即使是使用其母病毒的50%致死剂量（LD50）的100倍，这种减活的疫苗在成年或者新生实验鼠中也只产生暂时的轻微感染症状。单次接种此种减活病毒就能在实验鼠上彻底保护H1N1,H3N2以及H5N1流感的感染，并且在实验雪貂上加速病毒的清除。从接种疫苗后的实验鼠身上分离的T细胞，再移植这些T细胞到接受的实验鼠，也被证明这些移植的T细胞有更强的抵抗流感病毒的能力。

此项研究证明了对于活病毒运用突变技术快速建立减活病毒库，然后运用高通量筛选系统发现能够对抗病毒的潜在疫苗，从而开发疫苗的可行性和理论基础。对于突发的流行性病毒感染的应对及疫苗开发，给出了重要的可行方案。

原始出处：
Lulan Wang, Su-Yang Liu, Hsiang-Wen Chen et al. Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and Ferrets. Cell Host&Microbe, Volume 21, Issue 3, p334–343, 8 March 2017, DOI: http://dx.doi.org/10.1016/j.chom.2017.02.007

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084174, encodeId=67db20841e4a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Nov 28 11:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857405, encodeId=5932185e405d9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue May 30 09:49:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960050, encodeId=1cb3196005052, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri May 05 21:49:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869791, encodeId=e5c31869e9198, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 05 09:49:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179175, encodeId=f41b1e9175df, content=跟进热点，信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:56 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-11-28 xjy02

    #Micro#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2084174, encodeId=67db20841e4a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Nov 28 11:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857405, encodeId=5932185e405d9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue May 30 09:49:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960050, encodeId=1cb3196005052, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri May 05 21:49:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869791, encodeId=e5c31869e9198, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 05 09:49:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179175, encodeId=f41b1e9175df, content=跟进热点，信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:56 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-05-30 jiafufeng@yaho

    #CRO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2084174, encodeId=67db20841e4a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Nov 28 11:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857405, encodeId=5932185e405d9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue May 30 09:49:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960050, encodeId=1cb3196005052, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri May 05 21:49:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869791, encodeId=e5c31869e9198, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 05 09:49:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179175, encodeId=f41b1e9175df, content=跟进热点，信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:56 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-05-05 维他命

    #CEL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2084174, encodeId=67db20841e4a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Nov 28 11:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857405, encodeId=5932185e405d9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue May 30 09:49:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960050, encodeId=1cb3196005052, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri May 05 21:49:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869791, encodeId=e5c31869e9198, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 05 09:49:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179175, encodeId=f41b1e9175df, content=跟进热点，信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:56 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-12-05 zhaozhouchifen

    #Cell#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2084174, encodeId=67db20841e4a6, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue Nov 28 11:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857405, encodeId=5932185e405d9, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue May 30 09:49:00 CST 2017, time=2017-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960050, encodeId=1cb3196005052, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri May 05 21:49:00 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869791, encodeId=e5c31869e9198, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 05 09:49:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179175, encodeId=f41b1e9175df, content=跟进热点，信息丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Mar 11 20:52:56 CST 2017, time=2017-03-11, status=1, ipAttribution=)]
    2017-03-11 虈亣靌

    跟进热点，信息丰富

    0

相关资讯

JAMA Pediatr：准妈妈请放心：怀孕期间接种流感疫苗不会增加孩子自闭症谱系障碍风险

怀孕期间母亲感染和发热与自闭症谱系障碍（ASD）的风险增加有关。但目前还没有研究调查怀孕期间流感疫苗接种与ASD之间的关联。来自美国的研究人员开展了一项研究，该研究的目的是探讨怀孕期间流感病毒感染和接种疫苗与ASD风险之间的关系。该队列研究共包括从2000年1月1日到2010年12月31日出生在北加利福尼亚Kaiser Permanente的196929个孩子，这些孩子都在至少24周胎龄时出生。该

Pediatrics：孕妇接种流感疫苗可降低新生儿感染的发生风险

BMJ研究新闻：孕妇接种流感疫苗可降低新生儿感染的发生风险美国的一项新的研究发现，与孕期并未接种流感疫苗的女性相比，孕期接种疫苗的女性其后代出生后前六个月流感样疾病的发生可减少61%， 实验室确诊的流感可减少70%，实验室确诊的流感相关的住院治疗可减少81%，该研究成果已在线发表于Pediatrics。目前的流感疫苗并不能在生命的最初六个月保护婴儿，因为它们并不能引起新生儿足够的免疫反应，但是在女

十个问题，终极解读流感疫苗！

一、问：什么是流感疫苗？ 答：流感疫苗是可以保护你避免病毒感染的一种治疗方法。流感是一种感染，可以引起发热、咳嗽、身体疼痛和其他症状。流感有不同的种类，包括“季节性流感”、2009年至2010年爆发的H1N1流感（也称为猪流感）和禽流感，这些流感都是病毒感染引起的。流感的医学专业术语是流行性感冒，疫苗的专业术语是接种疫苗或免疫接种。 这篇文章介绍的是可以避免季节性流感的流感疫苗

Clinical Infectious Diseases：孕妇接种季节性流感疫苗可使死胎率减半

在美国,死胎的发生率约为1%,每年约有24000个婴儿胎死腹中。 虽然导致死胎的具体原因尚不清楚,但研究人员认为，胎儿出生缺陷、胎盘功能障碍和脐带遗传问题及母亲疾病等因素也起到了一定作用。 35岁以上、孕期吸烟、孕妇肥胖或既往发生流产或或多胎妊娠的孕妇发生死产的风险更大。由于孕妇发生死产的原因无法确定，因此医生建议孕妇采用预防性保护策略。在一项新的研究中,Annette Regan博士和同事对澳大

Ann Intern Med：流感疫苗经鼻给药的效果不差于静脉注射

据发表于Annals of Internal Medicine的一项随机研究显示，流感病毒减毒活疫苗经鼻给药可获得和注射灭活流感疫苗相似的机体免疫。 在六月流感疫苗的效力成为头条，美国疾病控制和预防中心咨询委员会建议在2016-17年流感季节为儿童接种疫苗，因为在过去三个流感季节，吸入疫苗似乎并没有效果。英国公共卫生支持儿童疫苗项目中使用吸入性疫苗，他们认为此种接种方法可以预防50%以上的孩

Nat Commun：重大突破——终身有效的流感疫苗

如果只需要注射一次疫苗就可以终身不得流感，这该多好啊。现在科学家们似乎找到了制造这种疫苗的关键。 复旦大学和墨尔本大学的研究人员发现，有一种杀死流感的免疫细胞可以记住病毒株。这项研究发表在五月十三日的 Nature Communications 杂志上，文章的通讯作者是复旦大学的徐建青（Jianqing Xu）研究员和墨尔本大学的Katherine Kedzierska。

Baidu
map
Baidu
map
Baidu
map